文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV感染者多替拉韦单药治疗的长期随访

Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该回顾性观察研究纳入61例病毒学抑制≥6个月、既往无整合酶抑制剂治疗失败史并换用多替拉韦单药(50 mg/日)的HIV感染者,报告第48周与第96周病毒学失败比例,并评估残留病毒血症与HIV DNA变化。结果显示病毒学失败概率均为5.6%(95%CI 1.8%-16.4%),失败者出现整合酶抑制剂耐药。

要点

  • 多替拉韦单药在既往长期病毒学抑制、低HIV储存库患者中病毒学失败风险低。
  • 3例病毒学失败均发生在第24周前,且均有整合酶抑制剂暴露史,并出现耐药。
  • 第48周与第96周病毒学失败概率均为5.6%(95%CI 1.8%-16.4%)。

核心结论

  • 在既往长期病毒学抑制且HIV储存库低的筛选人群中,多替拉韦单药长期随访显示病毒学失败风险低。

研究设计与样本

  • 回顾性观察研究,纳入61例病毒学抑制≥6个月、既往无整合酶抑制剂病毒学失败史并换用多替拉韦单药(50 mg/日)的患者。

主要发现

  • 病毒学失败均发生在第24周前,且见于既往有整合酶抑制剂暴露的患者。
  • 第48周病毒学失败概率为5.6%(95%CI=1.8%-16.4%),第96周结果相同。
  • 可检测残留病毒血症未增加,HIV DNA中位数无显著变化(基线2.4 log/10^6细胞,第48周2.3 log/10^6细胞)。
  • 22例患者的41/41份样本多替拉韦血浆浓度高于IC90。

关键数值与推荐

  • 多替拉韦单药剂量为50 mg/日;换药前中位抗逆转录病毒暴露15.4(IQR 6.5-19.9)年、病毒抑制5.8(IQR 3.2-10.3)年、CD4+计数687(IQR 461-848)细胞/mm3。
  • 多替拉韦单药治疗中位时长100(IQR 29-148)周。

临床怎么用

  • 多替拉韦单药不宜作为普遍方案,仅可考虑用于既往长期病毒学抑制、无整合酶抑制剂失败史且HIV储存库低的筛选患者,并需早期监测病毒学。
  • 因病毒学失败均发生在第24周前并伴整合酶抑制剂耐药,换药后早期应加密病毒载量监测。

局限性

  • 为单中心回顾性观察研究,样本量61例,随访至第96周者仅32例(52.5%)。
  • 研究人群经过筛选(既往长期病毒学抑制、低HIV储存库、无整合酶抑制剂失败史),结论外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, dolutegravir monotherapy has been explored as a drug-reduced regimen for HIV patients. METHODS: This was a retrospective observational study, including patients virologically suppressed for ≥6 months, without previous virological failure (VF) under integrase inhibitors (INIs), who had been switched to dolutegravir monotherapy (50 mg/day). The primary aim was to report the proportion of VF at week 48 (W48) and week 96 (W96) of dolutegravir monotherapy. The evolution from baseline to W48 of residual viraemia on ultra-deep sequencing and HIV DNA was also evaluated. RESULTS: Sixty-one patients were included. Prior to switching to dolutegravir monotherapy, they had a median (IQR) of 15.4 (6.5-19.9) years of antiretroviral exposure, 5.8 (3.2-10.3) years of viral suppression and 687 (461-848) CD4+ cells/mm3. They remained on dolutegravir monotherapy for a median (IQR) of 100 (29-148) weeks. Forty-two out of 61 patients (68.9%) reached W48 and 32 out of 61 patients (52.5%) reached W96. VF occurred in three patients, with the emergence of INI resistance. VF occurred before W24 and in patients pre-exposed to INIs. At W48, the probability of VF (Kaplan-Meier analysis) was 5.6% (95% CI = 1.8%-16.4%). The same result was obtained at W96. Detectable residual viraemia did not increase and median HIV DNA did not change significantly (2.4 log/106 cells at baseline and 2.3 log/106 cells at W48). Dolutegravir plasma concentration was above the IC90 in 41/41 samples, from 22 patients. CONCLUSIONS: Long-term follow-up showed a low risk of VF under dolutegravir monotherapy, in a selected population of patients with previous long-term virological suppression and low HIV reservoir.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tebano G, Soulié C, Schneider L, et al. Long-term follow-up of HIV-infected patients on dolutegravir monotherapy. J Antimicrob Chemother. 2020. PMID: 31800056. doi:10.1093/jac/dkz478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。